Clinical Guest Contributors

  1. It Is Time To Require Human-Relevant Efficacy Evidence Before First-In-Human Trials 8/26/2026

    Why, when human-relevant evidence of likely efficacy can be generated before a trial begins, is it not evaluated before patients are exposed?

  2. Immune Priming, Oncolytic Viruses, And The Next Phase Of Solid Tumor Immunotherapy 8/25/2026

    Can priming with oncolytic viruses be a better path to reeducating the immune system to recognize and attack cancer? Oncolytics Biotech advisor Richard Vile, Ph.D., says yes.

  3. What BriaCell's Trial Design Says About Real-World Cancer Research 8/24/2026

    BriaCell President and CEO William Williams, MD, shares how broader eligibility criteria and physician’s choice controls can better reflect real-world cancer care.

  4. Accountability Gaps Can Break Clinical Supply Contracts 8/24/2026

    Contract gaps can create clinical supply failures when responsibilities differ across agreements. See how aligning obligations can prevent costly disputes, delays, and risks.

  5. 4 Ways That AI And Point-Of-Care Diagnostics Are Redefining Clinical Trial Design And Operations 8/24/2026

    Discover how AI-enhanced point-of-care diagnostics are changing trial design and what ClinOps should do next.

  6. 'How Do You Feel?': Designing A Cardiac Trial With A Patient-Reported Primary Endpoint 8/21/2026

    Imbria Pharmaceuticals' Albert Kim, MD, Ph.D., shares why PROs are the point of the company's FORTITUDE-HCM trial for patients with non-obstructive hypertrophic cardiomyopathy.

  7. Sustainable Patient Engagement: Your Enrollment And Representation Depend On It 8/21/2026

    Early and ongoing patient engagement is a crucial component to staving off recruitment trouble and securing proper patient representation. Boehringer Ingelheim's Karen Correa, Ph.D., explains how.

  8. The Reality Of Clinical Research Federal Funding Cuts 8/20/2026

    Although the most catastrophic federal funding cuts didn't come to fruition, Pamela Garzone discusses where some impacts are being felt now and will be felt for years to come.

  9. Stock Options: Choosing The Right Viral Inoculum For An Early-Phase Norovirus Trial 8/20/2026

    Viral stock can make or break a norovirus challenge study. Cocrystal Pharma's Sam Lee explains why inoculum quality, infectivity, and availability matter.

  10. Building The Execution Architecture For Real-World Data To Have Real-World Impact 8/20/2026

    RWE's next challenge is execution. Learn how life sciences orgns can turn evidence into sustained business and clinical impact.